Back to search

Article

Safety and Efficacy of Inactivated Sars-Cov-2 Vaccine in Patients with Rheumatic Diseases and Serum Antibody Changes Post-Omicron Variant Infection

2023-07-26

Abstract excerpt

Objective: The purpose of this study was to investigate whether the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has a similar efficacy and safety profile in patients with rheumatic and musculoskeletal diseases (RMDs) and healthy controls (HCs).<br><br>Methods: From 10 August 2021 to 30 September 2021, 134 HCs and 269 patients with RMDs were recruited, with all being vaccinated...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
23b6c849-1cab-52c6-8311-06f50bb0fc2d
DOI
10.2139/ssrn.4519855
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and Efficacy of Inactivated Sars-Cov-2 Vaccine in Patients with Rheumatic Diseases and Serum Antibody Changes Post-Omicron Variant InfectionDOI 10.2139/ssrn.4519855
COVID-19 Infection and Efficacy of Vaccination in Patients with Rheumatic Diseases During Omicron Outbreak in South Korea: A Prospective Cohort StudySemantic proximity
Immunogenicity and safety of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseasesSemantic proximity
Anti-SARS-CoV-2 immunogenicity decay and incident cases six months after Sinovac-CoronaVac inactivated vaccine in autoimmune rheumatic diseases patients: phase 4 prospective trialSemantic proximity
Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS – CoV ‐2 Messenger RNA VaccinationSemantic proximity
An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in ChileSemantic proximity
Efficacy and Safety of an Inactivated Whole-Virion Vaccine Against COVID-19, QazCovid-in®, In Healthy Adults: A Multicentre, Randomised, Single-Blind, Placebo-Controlled Phase 3 Clinical Trial With a 6-Month Follow-UpSemantic proximity
Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal diseaseSemantic proximity
Factors Associated with COVID-19 Breakthrough Infection in the Pre-Omicron Era Among Vaccinated Patients with Rheumatic Diseases: A Cohort StudySemantic proximity
Safety of Coronavac and ChAdOx1 Vaccines Against SARS-CoV-2 in Patients with Rheumatoid Arthritis Data from the Brazilian Multicentric Study SaferSemantic proximity
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescentsSemantic proximity
Hyper Production of Anti Spike Antibodies and Rheumatological Manifestations: Coincidence or Pathogenesis?Semantic proximity
Increased Risk of Myositis-Specific and Myositis-Associated Autoantibodies after COVID-19 pandemic and Vaccination: A Spanish Multicenter Collaborative StudySemantic proximity
Select a neighboring publication to make it the new centre.